Asthma and type 2 diabetes (T2D) are two chronic conditions that affect millions of people worldwide. Recent research has uncovered a surprising connection between a common diabetes medication and reduced asthma attacks. This discovery could have significant implications for individuals managing both conditions.

Understanding the Link Between Asthma and Diabetes

Asthma is a respiratory condition characterized by inflammation and narrowing of the airways, leading to difficulty breathing. Type 2 diabetes is a metabolic disorder where the body becomes resistant to insulin or doesn’t produce enough of it, resulting in high blood sugar levels.

It’s not uncommon for these two conditions to coexist. In fact, one in three adults with asthma also has obesity, and nearly half of these individuals have T2D. Obesity and T2D are known to worsen asthma symptoms and increase the risk of asthma attacks (also known as exacerbations).

The Role of Metformin

Metformin is the first-line medication prescribed for T2D. It’s well-known for its effectiveness, safety, and affordability. But beyond controlling blood sugar levels, metformin has been found to have anti-inflammatory effects that could benefit the lungs.

Recent studies suggest that metformin may reduce airway inflammation and prevent airway remodeling—a process where the structure of the airways changes, leading to worsening asthma symptoms.

Key Findings from the Latest Research

A comprehensive study published in JAMA Internal Medicine explored the relationship between metformin use and asthma attacks in adults with both asthma and T2D. The study analyzed data from over 2 million adults with asthma, using records from the UK’s Clinical Practice Research Datalink (CPRD) between 2004 and 2020.

Study Design

Researchers used two robust methods to ensure the reliability of their findings:

1. Self-Controlled Case Series (SCCS): This method compares the rate of asthma attacks before and after starting metformin within the same individuals.
2. Inverse Probability of Treatment Weighting (IPTW) Cohort Study: This approach creates a balanced comparison between new metformin users and non-users by adjusting for various factors like age, sex, and other health conditions.

Results

• Reduced Asthma Attacks with Metformin:
  • SCCS Analysis: There was a 32% reduction in asthma attacks after starting metformin. Specifically, the incidence rate ratio (IRR) was 0.68. An IRR less than 1 indicates a reduction in risk.
  • IPTW Cohort Analysis: Metformin users had a 24% lower risk of asthma attacks compared to non-users. The hazard ratio (HR) was 0.76.
• Rapid and Sustained Effect:
  • The reduction in asthma attacks was observed as early as the first three months after starting metformin and continued throughout the 12-month follow-up period.
• Add-On Medications:
  • Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): When used in addition to metformin, GLP-1 RAs were associated with an additional 40% reduction in asthma attacks.
• Consistency Across Different Groups:
  • The beneficial effect of metformin was consistent regardless of:
    • Body Mass Index (BMI): Effective in both overweight and normal-weight individuals.
    • Blood Sugar Levels: Worked in people with both controlled and uncontrolled diabetes.
    • Asthma Severity: Helped those with mild and severe asthma.

What Do These Numbers Mean?

• Incidence Rate Ratio (IRR): An IRR of 0.68 means there’s a 32% reduction in the rate of asthma attacks after starting metformin.
• Hazard Ratio (HR): An HR of 0.76 indicates a 24% lower chance of experiencing an asthma attack when using metformin compared to not using it.
• Number Needed to Treat (NNT): The NNT was calculated to be 14, meaning that 14 people need to be treated with metformin for one year to prevent one asthma attack.

Why Are These Findings Significant?

• Dual Benefits: Metformin not only manages blood sugar levels but may also reduce asthma attacks, offering dual benefits for patients with both conditions.
• Affordable and Accessible: Metformin is widely available and cost-effective, making it an accessible option for many patients.
• Potential for Repurposing: This research opens the door to repurposing existing medications to treat other conditions, accelerating the availability of new treatments without the lengthy process of developing new drugs.

Understanding the Potential Mechanisms

The exact way metformin reduces asthma attacks isn’t entirely clear, but several theories exist:

1. Anti-Inflammatory Effects: Metformin may reduce inflammation in the airways, which is a key factor in asthma attacks.
2. Reduction of Airway Remodeling: By preventing structural changes in the airways, metformin may keep them open and less reactive.
3. Activation of Protective Pathways: Metformin activates certain enzymes that help protect the lungs from damage.

Implications for Patients

If you have both asthma and type 2 diabetes, this research suggests that metformin could offer additional benefits beyond blood sugar control. However, it’s important to consult with your healthcare provider before making any changes to your medication regimen.

What About GLP-1 Receptor Agonists?

GLP-1 RAs are another class of diabetes medications that have shown promise in reducing asthma attacks when used alongside metformin. These medications not only help control blood sugar but also may have anti-inflammatory effects in the lungs.

Moving Forward

While these findings are encouraging, more research, including clinical trials, is needed to confirm the benefits of metformin and GLP-1 RAs in reducing asthma attacks. Healthcare providers should consider these potential benefits when prescribing medications to patients with both asthma and diabetes.

Conclusion

The intersection of asthma and type 2 diabetes presents unique challenges for patients and healthcare providers. The discovery that metformin, a common diabetes medication, may reduce asthma attacks offers hope for improved management of both conditions. As research progresses, patients can look forward to more integrated and effective treatment strategies.

Frequently Asked Questions (FAQs)

Can metformin really help with asthma?

According to recent research, metformin has been associated with a significant reduction in asthma attacks in individuals with both asthma and type 2 diabetes. Because of the drug’s safety record even among non-diabetic individuals, it is not unreasonable to print the original article for the physician to consider an off-label use of the drug.

Should I start taking metformin for my asthma?

Metformin is primarily prescribed for type 2 diabetes. If you have asthma but not diabetes, metformin is not typically recommended. Always consult your healthcare provider before starting any new medication.

What are GLP-1 receptor agonists?

GLP-1 receptor agonists are medications used to treat type 2 diabetes. They help lower blood sugar levels and, as recent studies suggest, may also reduce asthma attacks when used with metformin.  A GLP-1RA would be useful in the context of a patient that is requires addition asthma exacerbation 

How do these findings affect current asthma treatments?

Metformin should be seen as an addition to the medication regimen, so that other medications are used less frequently. Metformin is not intended to replace existing medications.

Disclaimer: This article is for informational purposes only and does not substitute professional medical advice. Always consult a qualified healthcare provider for guidance tailored to your health situation.

At CanadianInsulin.com, we’re dedicated to providing up-to-date information and quality medications to support your health needs. Explore our range of GLP-1 receptor agonists and consult with our pharmacists for more information.